This new CPB states that (i) benralizumab (Fasenra) is considered medically necessary as add-on maintenance treatment of severe asthma when criteria met, and (ii) benralizumab is considered experimental and investigational for the treatment of acute bronchospasm, status asthmaticus, and chronic obstructive pulmonary disease.